Abstract | INTRODUCTION: There is currently no Food and Drug Administration (FDA)-approved treatment for hypoactive sexual desire disorder (HSDD). FDA approval of products utilizing testosterone has been delayed due to possible safety concerns. Flibanserin, a 5-HT(1A) agonist, 5-HT(2) antagonist, and gepirone-ER, a 5-HT(1A) agonist, have been shown to have activity in treatment of HSDD. However, more recently, the FDA issued a non-approval letter for flibanserin. AIM: METHODS: At baseline and post-treatment visits, a trained psychiatrist made diagnoses of HSDD based on Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) criteria. Subjects meeting criteria for HSDD were followed to observe the effect of gepirone-ER (20-80 mg/day), comparator antidepressants ( fluoxetine, 20-40 mg/day or paroxetine, 10-40 mg/day), or placebo in reversing DSM-IV diagnosis. A subpopulation of women with Hamilton Depression Rating Scale (HAMD-17) entry scores of 18 or less was evaluated. Adverse events (AEs) of sexual dysfunction were also collected. MAIN OUTCOME MEASURE: Number (%) of patients who no longer met criteria for HSDD (percent resolved). RESULTS: Eight hundred seventy-five women (18-64 years of age, average 38 years old, ∼80% premenopausal) entered three studies; 668 (72.5%) completed. Only 161 (18.4%) met DSM-IV criteria for HSDD. Cumulatively, 63% of gepirone-ER-treated patients reversed their diagnosis of HSDD compared to 40% of placebo-treated patients at end point (8 weeks) (P = 0.007). Selective serotonin reuptake inhibitor-treated patients were not different from placebo. Significant results for gepirone-ER occurred by week 2 (P = 0.0001). Patients who were mildly depressed (HAMD scores of 18 or less) also improved at week 2 (P = 0.01) and week 8 (P = 0.07). Sexual dysfunction AEs were significantly less in gepirone-ER-treated patients than placebo (P = 0.013). CONCLUSIONS:
Gepirone-ER may have efficacy in the treatment of HSDD among depressed and possibly nondepressed women. Efficacy occurs by week 2, and does not seem to be purely an antidepressant effect.
|
Authors | Louis F Fabre, Candace S Brown, Louis C Smith, Leonard R Derogatis |
Journal | The journal of sexual medicine
(J Sex Med)
Vol. 8
Issue 5
Pg. 1411-9
(May 2011)
ISSN: 1743-6109 [Electronic] Netherlands |
PMID | 21324094
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Copyright | © 2011 International Society for Sexual Medicine. |
Chemical References |
- Antidepressive Agents
- Pyrimidines
- gepirone
|
Topics |
- Adolescent
- Adult
- Antidepressive Agents
(therapeutic use)
- Depressive Disorder, Major
(complications, psychology)
- Double-Blind Method
- Female
- Humans
- Libido
(drug effects)
- Middle Aged
- Pyrimidines
(therapeutic use)
- Sexual Dysfunctions, Psychological
(diagnosis, drug therapy, psychology)
- Treatment Outcome
- Young Adult
|